Moderna Shares Higher After Interim Data for Covid-19 Vaccine in Children
October 25 2021 - 1:43PM
Dow Jones News
By Michael Dabaie
Moderna Inc. shares were up 5% to $342.35 in afternoon trading
after the company said it had positive interim data from the Phase
2/3 study of its Covid-19 vaccine candidate in children age six to
11.
The interim analysis showed a robust neutralizing antibody
response after two doses of mRNA-1273 at the 50 microgram dose
level with a favorable safety profile, the company said Monday.
Moderna plans to submit the data to the Food and Drug
Administration, European Medicines Agency and other global
regulators in the near term.
The Moderna positive follows Pfizer recently saying it is
seeking emergency use authorization for its vaccine in
children.
Pfizer Inc. in early October said it and BioNTech officially
submitted a request to the FDA for emergency use authorization of
their Covid-19 vaccine in children ages five to 11.
Pfizer and BioNTech in late September unveiled results from a
Phase 2/3 trial showing a favorable safety profile and robust
neutralizing antibody responses in children five to 11 years of age
using a two-dose regimen administered 21 days apart, with a smaller
dose than that used for people 12 and older.
Pfizer in September said results in children under five years of
age are expected as soon as later this year.
Write to Michael Dabaie at michael.dabaie@wsj.com
(END) Dow Jones Newswires
October 25, 2021 13:28 ET (17:28 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Moderna (NASDAQ:MRNA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Moderna (NASDAQ:MRNA)
Historical Stock Chart
From Sep 2023 to Sep 2024